Lotronex

(alosetron)

Phase 3Small molecule

LLegacy Health System

Lotronex is one of 34 small molecule programs targeting Irritable Bowel Syndrome. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Irritable Bowel SyndromeActive, not recruiting

Irritable Bowel SyndromePhase 3

Active, not recruiting

Competition

Competitive Landscape

185 competitors in Irritable Bowel Syndrome

#DrugCompanyPhaseTrials

Lialda

Takeda

Phase 3

2 2

Xifaxan

SSalix

Phase 3

10 3

Zofran

Novartis

Phase 3

1 4

Amitiza

SSucampo Pharma Americas, LLC

Phase 3

5 5

Circadin

NNeurim Pharmaceuticals Ltd.

Phase 3

1 6

Zarontin

PParkedale

Phase 3

1 7

Mesalazine

Ferring

Phase 3

4 8

Saccharomyces Boulardii

BBiocodex

Phase 3

3 9

Trulance

SSalix

Phase 3

4 10

Lotronex

LLegacy Health System

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Irritable Bowel Syndrome2 trials

Study In Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy

Completed· GSK logo

GSK·Phase 3·NCT00067457·700 enrolled

Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy

Completed· GSK logo

GSK·Phase 3·NCT00067561·702 enrolled

ESS1 trial

Study to Assess the Effect Of Alosetron On Mucosal Blood Flow

Completed· GSK logo

GSK·Phase 4·NCT00370032·49 enrolled

Regulatory

FDA Approval Timeline[4]

Dec 23, 2003

LOTRONEX

NDA NDA021107

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for alosetron. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — alosetron compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for alosetron. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA021107). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Legacy Health System company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: LLegacy Health System

Lotronex

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Irritable Bowel Syndrome2 trials

ESS1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News